Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, Read More
Multicenter study of over 1000 females with breast cancer, Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More
Four additional poster presentations from the ongoing real-world FLEX Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, Read More
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® Read More
FLEX Study reaches milestone of 20,000 enrolled patients, providing Read More
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among Read More
Poster presentation to highlight new data on MammaPrint® and Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 11, Read More
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Read More